Company Oramed Pharmaceuticals, Inc. OTC Bulletin Board
Equities
US68403P1049
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
15/05 | Compugen Names David Silberman CFO | MT |
09/05 | Oramed Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical Solutions
100.0
%
| 3 | 100.0 % | 1 | 100.0 % | -50.43% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Israel
100.0
%
| 3 | 100.0 % | 1 | 100.0 % | -50.43% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Miriam Kidron
FOU | Founder | 83 | 12/02/12 |
Nadav Kidron
CEO | Chief Executive Officer | 50 | 12/02/12 |
Joshua Hexter
COO | Chief Operating Officer | 53 | 14/13/14 |
Leonard Sank
BRD | Director/Board Member | 59 | 23/07/23 |
Zach Herschfus
IRC | Investor Relations Contact | - | - |
Netanel Derovan
LAW | General Counsel | - | 09/22/09 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Nadav Kidron
CEO | Chief Executive Officer | 50 | 12/02/12 |
Miriam Kidron
FOU | Founder | 83 | 12/02/12 |
Leonard Sank
BRD | Director/Board Member | 59 | 23/07/23 |
Arie Mayer
BRD | Director/Board Member | 67 | 05/19/05 |
Benjamin Shapiro
BRD | Director/Board Member | 40 | 01/23/01 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 40,628,924 | 36,048,800 ( 88.73 %) | 0 | 88.73 % |
Company contact information
Oramed Pharmaceuticals, Inc.
1185 Avenue of the Americas 3rd Floor
10036, New York
+844 967 2633
http://www.oramed.comSector
1st Jan change | Capi. | |
---|---|---|
+64.92% | 62.86B | |
-1.85% | 41.38B | |
+45.77% | 40.38B | |
-8.93% | 27.64B | |
+13.05% | 26.46B | |
-21.96% | 18.9B | |
+4.21% | 12.67B | |
+25.74% | 12.27B | |
+27.42% | 12.07B |
- Stock Market
- Equities
- ORMP Stock
- Stock
- Company Oramed Pharmaceuticals, Inc.